Curis is an oncology-focused company seeking to develop and commercialize next generation targeted drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also developing its pipeline of proprietary targeted cancer drug candidates, including CUDC-427, a small molecule antagonist of IAP proteins; CUDC-907, a dual PI3K and HDAC inhibitor; and CUDC-101, an EGFR/Her2 and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.
Curis is developing several proprietary clinical-stage small molecules in testing for various cancers, including antagonist of IAP proteins CUDC-427, dual PI3K and HDAC inhibitor CUDC-907 and EGFR/Her2 and HDAC inhibitor CUDC-101.
Curis’ collaborator Genentech (Roche) is commercializing Hedgehog pathway inhibitor Erivedge® (vismodegib) in the U.S. for advanced basal cell carcinoma. Roche continues to seek approvals for Erivedge in several different territories in this lead indication and is also testing Erivedge in less severe forms of BCC. Several additional clinical studies are ongoing under collaborations between Genentech and the National Cancer Institute and independent study investigators.
Curis licensee Debiopharm is also conducting clinical studies on HSP90 inhibitor Debio 0932 in patients with advanced lung cancer and expects to initiate additional testing in patients with renal cell carcinoma during the second half of 2013.
Scientist – Preclinical & Translational Biomarker:
Curis is seeking a highly motivated scientist to join an established preclinical and translational biomarker group working on understanding the mechanism of novel cancer drug candidate actions, and developing combination therapy strategies. This position requires experience with design, execution, and management of preclinical studies, and generation of reports of results. He or she will be expected to interpret data and adapt a course of action as necessary. The successful candidate will be capable of assuming responsibility for high profile projects with a significant impact on scientific and translational programs. Responsibilities include overseeing daily scientific activity of Research Associates, including providing technical support in cell biology and molecular biology assay development, making and reviewing work assignments, establishing priorities, and resolving problems; applying independent scientific judgment in preclinical biomarker studies; and managing external resources andcollaborations.
This position requires a Ph.D., with a minimum of 4 years relevant industry experience in cancer drug discovery. Experience with small molecule inhibitors in oncology indications is highly desired. Experience in managing CROs or academic collaborations is preferred. The successful candidate will be capable of managing multiple tasks effectively. Excellent writing, data analysis, presentation and communication skills, and the ability to work in a team environment, are essential.
Please send CV with job code (SCO200) to:
Human Resources, Curis, Inc.
Qualified candidates should submit their CVs, with job code, via email to firstname.lastname@example.org, via fax to 617-503-6501, or mail to:
No phone calls please.
Curis, Inc. is an Equal Opportunity Employer.